CVRx, Inc. (CVRX)

Market Cap	293.83M
Revenue (ttm)	47.26M
Net Income (ttm)	-58.48M
Shares Out	24.26M
EPS (ttm)	-2.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	271,133
Open	11.56
Previous Close	11.72
Day's Range	11.39 - 12.28
52-Week Range	6.40 - 33.14
Beta	1.16
Analysts	Buy
Price Target	16.67 (+37.66%)
Earnings Date	Jan 23, 2025

About CVRX

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 an...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 30, 2021
• Employees: 200
• Stock Exchange: NASDAQ
• Ticker Symbol: CVRX
• Website: https://www.cvrx.com

Financial Performance

In 2023, CVRx, Inc.'s revenue was $39.30 million, an increase of 74.89% compared to the previous year's $22.47 million. Losses were -$41.20 million, -0.55% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for CVRX stock is "Buy." The 12-month stock price forecast is $16.67, which is an increase of 37.66% from the latest price.

Price Target

$16.67

(37.66% upside)

Analyst Consensus: Buy